These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 16133418)

  • 21. EGFR intragenic loss and gene amplification in astrocytic gliomas.
    Arjona D; Bello MJ; Rey JA
    Cancer Genet Cytogenet; 2006 Jan; 164(1):39-43. PubMed ID: 16364761
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular analysis of the erbB gene family calmodulin-binding and calmodulin-like domains in astrocytic gliomas.
    Arjona D; Bello MJ; Alonso ME; Gonzalez-Gomez P; Lomas J; Aminoso C; Lopez-Marin I; Isla A; De Campos JM; Vaquero J; Gutierrez M; Villalobo A; Rey JA
    Int J Oncol; 2004 Nov; 25(5):1489-94. PubMed ID: 15492843
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reliability of differential PCR for the detection of EGFR and MDM2 gene amplification in DNA extracted from FFPE glioma tissue.
    Hunter SB; Abbott K; Varma VA; Olson JJ; Barnett DW; James CD
    J Neuropathol Exp Neurol; 1995 Jan; 54(1):57-64. PubMed ID: 7815080
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Amplification of epidermal growth factor receptor gene in gliomas: histopathology and prognosis.
    Hurtt MR; Moossy J; Donovan-Peluso M; Locker J
    J Neuropathol Exp Neurol; 1992 Jan; 51(1):84-90. PubMed ID: 1311022
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecular features of adult glioma associated with patient race/ethnicity, age, and a polymorphism in O6-methylguanine-DNA-methyltransferase.
    Wiencke JK; Aldape K; McMillan A; Wiemels J; Moghadassi M; Miike R; Kelsey KT; Patoka J; Long J; Wrensch M
    Cancer Epidemiol Biomarkers Prev; 2005 Jul; 14(7):1774-83. PubMed ID: 16030116
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Monosomy of chromosome 10 associated with dysregulation of epidermal growth factor signaling in glioblastomas.
    Yadav AK; Renfrow JJ; Scholtens DM; Xie H; Duran GE; Bredel C; Vogel H; Chandler JP; Chakravarti A; Robe PA; Das S; Scheck AC; Kessler JA; Soares MB; Sikic BI; Harsh GR; Bredel M
    JAMA; 2009 Jul; 302(3):276-89. PubMed ID: 19602687
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lack of prognostic relevance of alterations in the epidermal growth factor receptor-transforming growth factor-alpha pathway in human astrocytic gliomas.
    Waha A; Baumann A; Wolf HK; Fimmers R; Neumann J; Kindermann D; Astrahantseff K; Blümcke I; von Deimling A; Schlegel U
    J Neurosurg; 1996 Oct; 85(4):634-41. PubMed ID: 8814167
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical insights gained by refining the 2016 WHO classification of diffuse gliomas with: EGFR amplification, TERT mutations, PTEN deletion and MGMT methylation.
    Brito C; Azevedo A; Esteves S; Marques AR; Martins C; Costa I; Mafra M; Bravo Marques JM; Roque L; Pojo M
    BMC Cancer; 2019 Oct; 19(1):968. PubMed ID: 31623593
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Relationship between EGFR overexpression and gene amplification status in central nervous system gliomas.
    Tripp SR; Willmore-Payne C; Layfield LJ
    Anal Quant Cytol Histol; 2005 Apr; 27(2):71-8. PubMed ID: 15913199
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pretreatment Dynamic Susceptibility Contrast MRI Perfusion in Glioblastoma: Prediction of EGFR Gene Amplification.
    Gupta A; Young RJ; Shah AD; Schweitzer AD; Graber JJ; Shi W; Zhang Z; Huse J; Omuro AM
    Clin Neuroradiol; 2015 Jun; 25(2):143-50. PubMed ID: 24474262
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme.
    Shinojima N; Tada K; Shiraishi S; Kamiryo T; Kochi M; Nakamura H; Makino K; Saya H; Hirano H; Kuratsu J; Oka K; Ishimaru Y; Ushio Y
    Cancer Res; 2003 Oct; 63(20):6962-70. PubMed ID: 14583498
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Epidermal growth factor receptor (EGFR) gene amplification in high-grade gliomas: Western Indian tertiary cancer center experience.
    Shelly D; Epari S; Arora I; Pai T; Ahmed S; Moiyadi A; Chinnaswamy G; Gupta T; Goda J; Shetty P; Kane SV; Desai SB; Jalali R
    Neurol India; 2016; 64(1):115-20. PubMed ID: 26755002
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Analysis of p53 mutation and epidermal growth factor receptor amplification in recurrent gliomas with malignant progression.
    Reifenberger J; Ring GU; Gies U; Cobbers L; Oberstrass J; An HX; Niederacher D; Wechsler W; Reifenberger G
    J Neuropathol Exp Neurol; 1996 Jul; 55(7):822-31. PubMed ID: 8965097
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Study on the expression of epidermal growth factor receptor and p53 in astrocytic gliomas: evidence for a distinct genetic pathway].
    Dong L; Pu PY; Wang H; Wang GX; Kang CS; Jiao DR
    Zhonghua Bing Li Xue Za Zhi; 2006 Apr; 35(4):232-6. PubMed ID: 16776982
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reverse transcriptase polymerase chain reaction as a reliable method to detect epidermal growth factor receptor exon 2-7 gene deletion in human glioblastomas.
    Worm K; Dabbagh P; Schwechheimer K
    Hum Pathol; 1999 Feb; 30(2):222-7. PubMed ID: 10029453
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Concurrent EGFR amplification and TP-53 mutation in glioblastomas.
    Gil-Benso R; Lopez-Gines C; Benito R; López-Guerrero JA; Callaghan RC; Pellín A; Roldán P; Cerdá-Nicolas M
    Clin Neuropathol; 2007; 26(5):224-31. PubMed ID: 17907599
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Activation of STAT3, MAPK, and AKT in malignant astrocytic gliomas: correlation with EGFR status, tumor grade, and survival.
    Mizoguchi M; Betensky RA; Batchelor TT; Bernay DC; Louis DN; Nutt CL
    J Neuropathol Exp Neurol; 2006 Dec; 65(12):1181-8. PubMed ID: 17146292
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Defining EGFR amplification status for clinical trial inclusion.
    French PJ; Eoli M; Sepulveda JM; de Heer I; Kros JM; Walenkamp A; Frenel JS; Franceschi E; Clement PM; Weller M; Ansell P; Looman J; Bain E; Morfouace M; Gorlia T; van den Bent M
    Neuro Oncol; 2019 Oct; 21(10):1263-1272. PubMed ID: 31125418
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Correlation of EGFR, IDH1 and PTEN status with the outcome of patients with recurrent glioblastoma treated in a phase II clinical trial with the EGFR-blocking monoclonal antibody cetuximab.
    Lv S; Teugels E; Sadones J; De Brakeleer S; Duerinck J; Du Four S; Michotte A; De Grève J; Neyns B
    Int J Oncol; 2012 Sep; 41(3):1029-35. PubMed ID: 22752145
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Changes in the EGFR amplification and EGFRvIII expression between paired primary and recurrent glioblastomas.
    van den Bent MJ; Gao Y; Kerkhof M; Kros JM; Gorlia T; van Zwieten K; Prince J; van Duinen S; Sillevis Smitt PA; Taphoorn M; French PJ
    Neuro Oncol; 2015 Jul; 17(7):935-41. PubMed ID: 25691693
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.